FDA's Throckmorton Says There Is No "Systematic Conservatism" On Diabetes Drugs
This article was originally published in Pharmaceutical Approvals Monthly
Based on the number of investigational new drug applications submitted and meetings requested with FDA, the agency's requirements for studying the cardiovascular safety of diabetes drugs have not had a dramatically negative effect on innovation, despite “allegations” to the contrary, asserted the agency’s deputy director Douglas Throckmorton at the American Diabetes Association meeting.
You may also be interested in...
Venture capitalists are reevaluating type 2 diabetes investments in light of daunting new regulatory hurdles and an economic climate that limits their ability to cash out of such companies in a timely fashion. But, say some VCs, truly innovative compounds may be worth the bigger R&D bills and longer time to exit given the dazzlingly large market at stake
In raising pre-market safety standards, FDA says that development time will not necessarily increase if a robust protocol is used.